Optimizing the Cell Painting assay for image-based profiling.

Autor: Cimini BA; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Chandrasekaran SN; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kost-Alimova M; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Miller L; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Goodale A; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Fritchman B; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Byrne P; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Garg S; Merck Healthcare KGaA, Darmstadt, Germany., Jamali N; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Logan DJ; Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA., Concannon JB; Chemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Lardeau CH; Janssen Pharmaceutica N.V., Beerse, Belgium., Mouchet E; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Singh S; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Shafqat Abbasi H; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Aspesi P Jr; Chemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Boyd JD; Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA., Gilbert T; Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA., Gnutt D; Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany., Hariharan S; Discovery Sciences, Pfizer, Groton, CT, USA., Hernandez D; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hormel G; Merck Healthcare KGaA, Darmstadt, Germany., Juhani K; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Melanson M; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Mervin LH; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Monteverde T; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Pilling JE; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Skepner A; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Swalley SE; Biogen, Inc., Cambridge, MA, USA., Vrcic A; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Weisbart E; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Williams G; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Yu S; Takeda Development Center Americas, Inc., San Diego, CA, USA., Zapiec B; Merck Healthcare KGaA, Darmstadt, Germany., Carpenter AE; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA. anne@broadinstitute.org.

Publikováno v: Nature protocols [Nat Protoc] 2023 Jul; Vol. 18 (7), pp. 1981-2013. Date of Electronic Publication: 2023 Jun 21.

Protein kinase A activation inhibits DUX4 gene expression in myotubes from patients with facioscapulohumeral muscular dystrophy.

Autor: Cruz JM; From Musculoskeletal Diseases and., Hupper N; From Musculoskeletal Diseases and., Wilson LS; From Musculoskeletal Diseases and., Concannon JB; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Wang Y; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Oberhauser B; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Patora-Komisarska K; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Zhang Y; From Musculoskeletal Diseases and., Glass DJ; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Trendelenburg AU; From Musculoskeletal Diseases and., Clarke BA; From Musculoskeletal Diseases and Brian.Clarke@novartis.com.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2018 Jul 27; Vol. 293 (30), pp. 11837-11849. Date of Electronic Publication: 2018 Jun 13.